Literature DB >> 23093560

Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3.

Nicolas Wentzensen1, Chang Sun, Arpita Ghosh, Walter Kinney, Lisa Mirabello, Sholom Wacholder, Ruth Shaber, Brandon LaMere, Megan Clarke, Attila T Lorincz, Philip E Castle, Mark Schiffman, Robert D Burk.   

Abstract

BACKGROUND: Persistent infections with carcinogenic human papillomavirus (HPV) types are the necessary cause of cervical cancer. We recently demonstrated that the HPV16 genome is strongly methylated in cervical precancer compared with transient infections. However, the extent of methylation in other HPV types and its role in progression to cancer is poorly understood.
METHODS: We analyzed whole-genome methylation patterns of the three next most carcinogenic HPV genotypes: HPV31 (closely related to HPV16), and two other closely related types, HPV18 and HPV45. DNA was extracted from cervical cytology specimens from 92 women with precancer and 96 women infected with HPV31, HPV18, or HPV45, but who had no cytological or histological abnormalities. After bisulfite modification, genome-wide pyrosequencing was performed covering 80-106 sites. We calculated differences in median methylation, odds ratios, areas under the curve, and Spearman rank correlation coefficients for methylation levels between different sites. All statistical tests were two-sided.
RESULTS: For all three HPV types, we observed strongly elevated methylation levels at multiple CpG sites in the E2, L2, and L1 regions among women with cervical intraepithelial neoplasia grade 3 compared with women with transient infections. We observed high correlation of methylation patterns between phylogenetically related types. The highest areas under the curve were 0.81 for HPV31, 0.85 for HPV18, and 0.98 for HPV45. Differential methylation patterns in cervical intraepithelial neoplasia grade 3 patients with multiple infections suggest that methylation can clarify which of the infections is causal.
CONCLUSIONS: Carcinogenic HPV DNA methylation indicates transforming HPV infections. Our findings show that methylation of carcinogenic HPV types is a general phenomenon that warrants development of diagnostic assays.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23093560      PMCID: PMC3571257          DOI: 10.1093/jnci/djs425

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  24 in total

1.  Molecular mechanisms of gene silencing mediated by DNA methylation.

Authors:  Michela Curradi; Annalisa Izzo; Gianfranco Badaracco; Nicoletta Landsberger
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

2.  Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a Costa Rican population.

Authors:  Lisa Mirabello; Chang Sun; Arpita Ghosh; Ana C Rodriguez; Mark Schiffman; Nicolas Wentzensen; Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Attila Lorincz; Robert D Burk
Journal:  J Natl Cancer Inst       Date:  2012-03-23       Impact factor: 13.506

Review 3.  Human papillomavirus and cervical cancer.

Authors:  Mark Schiffman; Philip E Castle; Jose Jeronimo; Ana C Rodriguez; Sholom Wacholder
Journal:  Lancet       Date:  2007-09-08       Impact factor: 79.321

4.  The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation.

Authors:  Sushma Badal; Vinay Badal; Itzel E Calleja-Macias; Mina Kalantari; Linda S H Chuang; Benjamin F L Li; Hans-Ulrich Bernard
Journal:  Virology       Date:  2004-07-01       Impact factor: 3.616

5.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

Authors:  N W J Bulkmans; J Berkhof; L Rozendaal; F J van Kemenade; A J P Boeke; S Bulk; F J Voorhorst; R H M Verheijen; K van Groningen; M E Boon; W Ruitinga; M van Ballegooijen; P J F Snijders; C J L M Meijer
Journal:  Lancet       Date:  2007-10-04       Impact factor: 79.321

6.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Authors:  Pontus Naucler; Walter Ryd; Sven Törnberg; Anders Strand; Göran Wadell; Kristina Elfgren; Thomas Rådberg; Björn Strander; Bo Johansson; Ola Forslund; Bengt-Göran Hansson; Eva Rylander; Joakim Dillner
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

7.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

8.  Methylation of the human papillomavirus-18 L1 gene: a biomarker of neoplastic progression?

Authors:  Tolga Turan; Mina Kalantari; Itzel E Calleja-Macias; Heather A Cubie; Kate Cuschieri; Luisa L Villa; Hanne Skomedal; Hugo A Barrera-Saldaña; Hans-Ulrich Bernard
Journal:  Virology       Date:  2006-02-10       Impact factor: 3.616

Review 9.  Papillomavirus life cycle organization and biomarker selection.

Authors:  John Doorbar
Journal:  Dis Markers       Date:  2007       Impact factor: 3.434

Review 10.  Biomarkers in cervical cancer screening.

Authors:  Nicolas Wentzensen; Magnus von Knebel Doeberitz
Journal:  Dis Markers       Date:  2007       Impact factor: 3.434

View more
  60 in total

1.  A Suggested Approach to Simplify and Improve Cervical Screening in the United States.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

2.  [Epidemiology, prevention and early detection of cervical cancer].

Authors:  Nicolas Wentzensen
Journal:  Onkologe (Berl)       Date:  2016-08-04       Impact factor: 0.234

3.  Epigenetics of human papillomaviruses.

Authors:  Eric Johannsen; Paul F Lambert
Journal:  Virology       Date:  2013-08-13       Impact factor: 3.616

Review 4.  Advances in technologies for cervical cancer detection in low-resource settings.

Authors:  Kathryn A Kundrod; Chelsey A Smith; Brady Hunt; Richard A Schwarz; Kathleen Schmeler; Rebecca Richards-Kortum
Journal:  Expert Rev Mol Diagn       Date:  2019-08-01       Impact factor: 5.225

5.  Automated Cervical Screening and Triage, Based on HPV Testing and Computer-Interpreted Cytology.

Authors:  Kai Yu; Noorie Hyun; Barbara Fetterman; Thomas Lorey; Tina R Raine-Bennett; Han Zhang; Robin E Stamps; Nancy E Poitras; William Wheeler; Brian Befano; Julia C Gage; Philip E Castle; Nicolas Wentzensen; Mark Schiffman
Journal:  J Natl Cancer Inst       Date:  2018-11-01       Impact factor: 13.506

6.  The road ahead for cervical cancer prevention and control.

Authors:  J E Tota; A V Ramana-Kumar; Z El-Khatib; E L Franco
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

Review 7.  Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention.

Authors:  Ana Gradíssimo; Robert D Burk
Journal:  Expert Rev Mol Diagn       Date:  2017-02-20       Impact factor: 5.225

Review 8.  Epigenetic research in cancer epidemiology: trends, opportunities, and challenges.

Authors:  Mukesh Verma; Scott Rogers; Rao L Divi; Sheri D Schully; Stefanie Nelson; L Joseph Su; Sharon A Ross; Susan Pilch; Deborah M Winn; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-10       Impact factor: 4.254

Review 9.  Human papillomavirus DNA methylation as a potential biomarker for cervical cancer.

Authors:  Megan A Clarke; Nicolas Wentzensen; Lisa Mirabello; Arpita Ghosh; Sholom Wacholder; Ariana Harari; Attila Lorincz; Mark Schiffman; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-10-03       Impact factor: 4.254

10.  Filling a gap in cervical cancer screening programmes.

Authors:  Nicolas Wentzensen; Mark Schiffman
Journal:  Lancet Oncol       Date:  2014-02-13       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.